29 AUG 2019


Angelini Pharma announces the acquisition of two OTC products from Sanofi in Germany and Austria

Angelini Pharma announces the acquisition of two Sanofi CHC brands in Germany and Austria for a total of € 47 M.

The acquired products include BoxaGrippal® (ibuprofen/pseudoephedrine), an OTC brand that provides effective temporary relief from a range of cold and flu symptoms, and Heumann, a brand of medicinal teas for the treatment of conditions including mild bladder and kidney problems, cough and intestinal pain.
Boxagrippal® was launched by Boehringer Ingelheim in 2013, and today ranks at the top of its category (#4 in Germany and #3 in Austria).
Heumann teas have a strong tradition of more than 60 years in herbal medicinal preparations.

The acquisition of these products supports Angelini Pharma both in strengthening its position in the OTC market and in consolidating its presence in Germany and Austria.
Boxagrippal® and Heumann Teas will join the main brand Tantum®, which has been successfully marketed in the two above-mentioned countries for many years.

We inform you that Angelini Holding S.p.A. uses cookies (small files saved on your hard disk) to improve your browsing experience on this site. Angelini Holding S.p.A. uses third party cookies that allow third parties to access personal data collected during navigation. By continuing to browse the site, by accessing any area of it or selecting an element of it (for example, an image or a link) you consent to the use of cookies. At the following link you will find our extended information on cookies with a description of the categories present and links to the information of third parties as independent data controllers and you will have the opportunity to decide which cookies to authorize or whether to deny consent to all or only some cookies CONTINUE